Literature DB >> 8957154

The management of malignant hypercalcaemia.

J Watters1, G Gerrand, D Dodwell.   

Abstract

Malignant hypercalcaemia is a common problem for cancer clinicians. However, the management of this condition has altered substantially over the last 10 years and the condition is usually amenable to modern treatment. A number of effective pharmacological agents are available in current practice. Bisphosphonate drugs, particularly clodronate and pamidronate, are confirmed as the mainstay of modern management. Bisphosphonates are effective and well tolerated when given intravenously. Many aspects of the actions of bisphosphonates are not well understood, and knowledge of their pharmacokinetics is limited.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957154     DOI: 10.2165/00003495-199652060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia.

Authors:  V Srámek; I Novák; M Matĕjovic; R Rokyta; M Nalos; P Hora; H Pittrová
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

2.  Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.

Authors:  Nirmeen A Sabry; Emad E Habib
Journal:  Med Oncol       Date:  2010-03-05       Impact factor: 3.064

Review 3.  Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Authors:  A J Coukell; A Markham
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 4.  Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Tongue squamous cell carcinoma producing both parathyroid hormone-related protein and granulocyte colony-stimulating factor: a case report and literature review.

Authors:  Naoki Kaneko; Shintaro Kawano; Ryota Matsubara; Yuichi Goto; Teppei Jinno; Yasuyuki Maruse; Taiki Sakamoto; Yuma Hashiguchi; Masakazu Iida; Seiji Nakamura
Journal:  World J Surg Oncol       Date:  2016-06-17       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.